Compare Illumina, Inc. (ILMN) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Kyndryl Holdings Inc — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B). The key difference: Illumina, Inc. is far larger — about 10.4× Kyndryl Holdings Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | KD | |
|---|---|---|
Market Cap | $27.94B | $2.69B |
Sector | Health | Technology |
52-Week High | $194.33 | $39.47 |
52-Week Low | $91.00 | $10.59 |
Enterprise Value | $29.33B | $5.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
KD trades at $12.19, up 0.33% on the day, with a neutral technical signal. The company reported revenue of $15.06B in 2025, with net income turning positive to $252M after three years of losses. Recent news includes a partnership with Microsoft for sovereignty solutions and ongoing legal investigations into officers and directors.
The outlook is mixed; improving profitability and a low P/E of 14.38 suggest value, but recent earnings misses and legal scrutiny pose risks. Analyst consensus is a $14.00 price target with a hold rating, indicating cautious optimism amid transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
